Kyverna Therapeutics’ treatment of myasthenia gravis was granted orphan status by the FDA, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
- Five new option listings and one option delisting on March 12th
- Kyverna Therapeutics, Stanford University to evaluate KYV-101 in MS
- DoorDash, Lyft upgraded: Wall Street’s top analyst calls
- Kyverna Therapeutics initiated with an Outperform at Leerink